Eledon pharmaceuticals reports first quarter 2024 operating and financial results

Completed oversubscribed $50 million private placement first participant dosed in clinical trial at university of chicago medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes reported updated data from ongoing phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation tegoprubart used as part of immunosuppressive treatment following the first-ever kidney xenotransplant irvine, calif., may 09, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported its first quarter 2024 operating and financial results and reviewed recent business highlights.
ELDN Ratings Summary
ELDN Quant Ranking